XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating Expenses:    
Research and development $ 3,179 $ 3,283
General and administrative 3,665 3,337
Total operating expenses 6,844 6,620
Operating loss (6,844) (6,620)
Other income (expense):    
Investment income, net 670 63
Other expense, net (13) (148)
Total other income (expense) 657 (85)
Net loss before benefit from income taxes and noncontrolling interests (6,187) (6,705)
Benefit from income taxes 0 (2,479)
Net loss (6,187) (4,226)
Less - net income attributable to noncontrolling interests 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (6,187) $ (4,226)
Basic and diluted loss per share    
Caladrius Biosciences, Inc. common stockholders - basic (in usd per share) $ (0.77) $ (1.05)
Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share) $ (0.77) $ (1.05)
Weighted average common shares outstanding    
Basic shares 7,987 4,037
Diluted shares 7,987 4,037